ReviewNanomaterials (Basel, Switzerland)2022
Light-Triggered Polymersome-Based Anticancer Therapeutics Delivery.
Review in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Advances in Polyethyleneimine-Derived Nanoformulations.Small science · 2026Review
- Nanoparticle-Based Radiosensitization in Breast Cancer: A Multimodal Approach to Therapy and Immune Regulation.Biotechnology journal · 2026Review
- Smart Vesicle Therapeutics: Engineering Precision at the Nanoscale.Pharmaceutics · 2025Review
- The simultaneous use of nanovesicles and magnetic nanoparticles for cancer targeting and imaging.Therapeutic delivery · 2025Review
- Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy.Drug design, development and therapy · 2025Review
- Generation of transgenic fish cell line with α-lactalbumin nanocarriers co-delivering Tol2 transposase mRNA and plasmids.iScience · 2024Article
- Polymersomes as Innovative, Stimuli-Responsive Platforms for Cancer Therapy.Pharmaceutics · 2024Review
- Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease.Drug delivery · 2023Article
- Nanomaterials in tumor immunotherapy: new strategies and challenges.Molecular cancer · 2023Review
- An Overview of Supramolecular Platforms Boosting Drug Delivery.Bioinorganic chemistry and applications · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polymersomes are biomimetic cell membrane-like model structures that are self-assembled stepwise from amphiphilic copolymers. These polymeric (nano)carriers have gained the scientific community's attention due to their biocompatibility, versatility, and higher stability than liposomes. Their tunable properties, such as composition, size, shape, and surface functional groups, extend encapsulation possibilities to either hydrophilic or hydrophobic cargoes (or both) and their site-specific delivery. Besides, polymersomes can disassemble in response to different stimuli, including light, for controlling the "on-demand" release of cargo that may also respond to light as photosensitizers and plasmonic nanostructures. Thus, polymersomes can be spatiotemporally stimulated by light of a wide wavelength range, whose exogenous response may activate light-stimulable moieties, enhance the drug efficacy, decrease side effects, and, thus, be broadly employed in photoinduced therapy. This review describes current light-responsive polymersomes evaluated for anticancer therapy. It includes light-activable moieties' features and polymersomes' composition and release behavior, focusing on recent advances and applications in cancer therapy, current trends, and photosensitive polymersomes' perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.